Evidence map›Paper›PMID 31386297›Full record

ArticleCancer medicine2019

Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients.

Yoshimi Kiyozumi, Hiroyuki Matsubayashi, Yasue Horiuchi, Satomi Higashigawa, Takuma Oishi, Masato Abe, Sumiko Ohnami, Kenichi Urakami, Takeshi Nagashima, Masatoshi Kusuhara and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yoshimi KiyozumiDivision of Genetic Medicine Promotion, Shizuoka Cancer Center, Shizuoka, Japan.
Hiroyuki MatsubayashiDivision of Genetic Medicine Promotion, Shizuoka Cancer Center, Shizuoka, Japan.ORCID https://orcid.org/0000-0002-7050-2351
Yasue HoriuchiDivision of Genetic Medicine Promotion, Shizuoka Cancer Center, Shizuoka, Japan.
Satomi HigashigawaDivision of Genetic Medicine Promotion, Shizuoka Cancer Center, Shizuoka, Japan.
Takuma OishiDivision of Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Masato AbeDivision of Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Sumiko OhnamiShizuoka Cancer Center Research Institute, Shizuoka, Japan.
Kenichi UrakamiShizuoka Cancer Center Research Institute, Shizuoka, Japan.
Takeshi NagashimaShizuoka Cancer Center Research Institute, Shizuoka, Japan.
Masatoshi KusuharaShizuoka Cancer Center Research Institute, Shizuoka, Japan.ORCID https://orcid.org/0000-0002-4153-1196
Hidehiko MiyakeDepartment of Genetic Counseling, Graduate School of Ochanomizu University, Tokyo, Japan.
Ken YamaguchiShizuoka Cancer Center Research Institute, Shizuoka, Japan.
Shizuoka Cancer Center · JPOchanomizu University · JP

Funding

Shizuoka prefecture
6 · The paper itself

Abstract

backgroundLynch syndrome (LS) is the commonest inherited cancer syndrome caused by pathogenic variants of germline DNA mismatch repair (g.MMR) genes. Genome-wide sequencing is now increasingly applied for tumor characterization, but not for g.MMR. The aim of this study was to evaluate the incidence and pathogenicity of g.MMR variants in Japanese cancer patients.

methodsFour g.MMR genes (MLH1, MSH2, MSH6, and PMS2) were analyzed by next generation sequencing in 1058 cancer patients (614 male, 444 female; mean age 65.6 years) without past diagnosis of LS. The g.MMR variant pathogenicity was classified based on the ClinVar 2015 database. Tumor MMR immunohistochemistry, microsatellite instability (MSI), and BRAF sequencing were also investigated in specific cases.

resultsOverall, 46 g.MMR variants were detected in 167 (15.8%) patients, 17 likely benign variants in 119 patients, 24 variants of uncertain significance (VUSs) in 68 patients, two likely pathogenic variants in two patients, and three pathogenic variants in three (0.3%) patients. The three pathogenic variants included two colorectal cancers with MLH1 loss and high MSI and one endometrial cancer with MSH6 loss and microsatellite stability. Two likely pathogenic variants were shifted to VUSs by ClinVar (2018). One colon cancer with a likely benign variant demonstrated MLH1 loss and BRAF mutation, but other nonpathogenic variants showed sustained MMR and microsatellite stability.

conclusionsUniversal sequencing of g.MMR genes demonstrated sundry benign variants, but only a small proportion of cancer patients had pathogenic variants. Pathogenicity evaluation using the ClinVar database agreed with MSI, MMR immunohistochemistry, and BRAF sequencing.

Indexed as

Germ-Line MutationAdolescentAdultAgedAged, 80 and overChildColorectal Neoplasms, Hereditary NonpolyposisDNA-Binding ProteinsDNA Mismatch RepairFemaleHigh-Throughput Nucleotide SequencingHumansJapanMaleMicrosatellite InstabilityMiddle AgedBRAF protein, humanDNA-Binding ProteinsG-T mismatch-binding proteinMismatch Repair Endonuclease PMS2MLH1 protein, humanMSH2 protein, humanMutL Protein Homolog 1MutS Homolog 2 ProteinPMS2 protein, humanProto-Oncogene Proteins B-rafexome sequencingLynch syndromemismatch repair genenext generation sequencingpathogenicityvariant of uncertain significance

Identifiers

PMID31386297
PMCPMC6745857
OpenAlexW2965234599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.